EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 157 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $461,574 | -24.9% | 82,424 | -29.7% | 0.00% | – |
Q1 2024 | $614,401 | +600.7% | 117,252 | +599.4% | 0.00% | – |
Q4 2023 | $87,681 | -68.8% | 16,765 | -6.0% | 0.00% | – |
Q3 2023 | $281,147 | -18.4% | 17,828 | +0.6% | 0.00% | – |
Q2 2023 | $344,555 | -82.3% | 17,724 | -74.2% | 0.00% | -100.0% |
Q1 2023 | $1,950,664 | -7.2% | 68,758 | -4.4% | 0.00% | 0.0% |
Q4 2022 | $2,102,718 | +17.4% | 71,937 | +6.1% | 0.00% | 0.0% |
Q3 2022 | $1,791,000 | -40.2% | 67,824 | +0.6% | 0.00% | 0.0% |
Q2 2022 | $2,996,000 | -8.3% | 67,421 | +2.2% | 0.00% | 0.0% |
Q1 2022 | $3,266,000 | -6.6% | 65,977 | -3.9% | 0.00% | 0.0% |
Q4 2021 | $3,496,000 | -10.1% | 68,655 | -1.5% | 0.00% | 0.0% |
Q3 2021 | $3,887,000 | -71.4% | 69,688 | -78.0% | 0.00% | -66.7% |
Q2 2021 | $13,581,000 | +1.0% | 317,320 | -1.5% | 0.00% | -25.0% |
Q1 2021 | $13,441,000 | -7.4% | 322,042 | +3.3% | 0.00% | 0.0% |
Q4 2020 | $14,512,000 | -19.1% | 311,634 | -26.2% | 0.00% | -33.3% |
Q3 2020 | $17,948,000 | -21.4% | 422,491 | -11.3% | 0.01% | -25.0% |
Q2 2020 | $22,845,000 | +53.2% | 476,153 | +46.9% | 0.01% | +33.3% |
Q1 2020 | $14,912,000 | -40.5% | 324,190 | -22.3% | 0.01% | -25.0% |
Q4 2019 | $25,066,000 | +25.1% | 417,216 | +17.8% | 0.01% | +60.0% |
Q3 2019 | $20,043,000 | -10.6% | 354,304 | -12.0% | 0.01% | -16.7% |
Q2 2019 | $22,427,000 | +65.8% | 402,792 | +50.4% | 0.01% | +20.0% |
Q1 2019 | $13,524,000 | +15.3% | 267,861 | -8.0% | 0.01% | +25.0% |
Q4 2018 | $11,730,000 | -69.2% | 291,142 | -47.1% | 0.00% | -66.7% |
Q3 2018 | $38,136,000 | +18.9% | 550,064 | +29.8% | 0.01% | +9.1% |
Q2 2018 | $32,066,000 | +52.2% | 423,817 | +6.0% | 0.01% | +37.5% |
Q1 2018 | $21,064,000 | -10.7% | 399,769 | -9.5% | 0.01% | -11.1% |
Q4 2017 | $23,591,000 | -17.5% | 441,622 | -7.9% | 0.01% | -18.2% |
Q3 2017 | $28,586,000 | -19.2% | 479,312 | +6.9% | 0.01% | 0.0% |
Q2 2017 | $35,363,000 | +165.9% | 448,250 | +179.5% | 0.01% | +175.0% |
Q1 2017 | $13,300,000 | +10.9% | 160,359 | +6.1% | 0.00% | 0.0% |
Q4 2016 | $11,996,000 | +22.8% | 151,196 | +8.4% | 0.00% | +33.3% |
Q3 2016 | $9,765,000 | +131.2% | 139,509 | +28.2% | 0.00% | +50.0% |
Q2 2016 | $4,223,000 | -20.9% | 108,845 | -17.5% | 0.00% | 0.0% |
Q1 2016 | $5,341,000 | -63.8% | 131,883 | -20.8% | 0.00% | -66.7% |
Q4 2015 | $14,766,000 | +24.1% | 166,530 | +3.6% | 0.01% | +20.0% |
Q3 2015 | $11,899,000 | +322.2% | 160,732 | +361.2% | 0.01% | +400.0% |
Q2 2015 | $2,818,000 | +4106.0% | 34,853 | +2078.3% | 0.00% | – |
Q1 2015 | $67,000 | +318.8% | 1,600 | +60.0% | 0.00% | – |
Q4 2014 | $16,000 | – | 1,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |